Ben Kozub - Cymabay Therapeu Head Commercial
Executive
Ben Kozub is Head Commercial of Cymabay Therapeu
| Phone | 510 293 8800 |
| Web | https://www.cymabay.com |
Cymabay Therapeu Management Efficiency
The company has return on total asset (ROA) of (0.2205) % which means that it has lost $0.2205 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6417) %, meaning that it created substantial loss on money invested by shareholders. Cymabay Therapeu's management efficiency ratios could be used to measure how well Cymabay Therapeu manages its routine affairs as well as how well it operates its assets and liabilities.Cymabay Therapeu currently holds 114.49 M in liabilities with Debt to Equity (D/E) ratio of 1.45, which is about average as compared to similar companies. Cymabay Therapeu has a current ratio of 11.96, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Cymabay Therapeu's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| CPA CPA | Viking Therapeutics | 54 | |
| Xichen Lin | Structure Therapeutics American | 51 | |
| Melissa Manno | Kiniksa Pharmaceuticals | N/A | |
| Prof MD | Day One Biopharmaceuticals | 55 | |
| Paul Cocja | Phathom Pharmaceuticals | N/A | |
| Lily Cheung | Pliant Therapeutics | 52 | |
| Eric Olson | Stoke Therapeutics | N/A | |
| Robyn MA | Acumen Pharmaceuticals | N/A | |
| Bob Gatmaitan | Structure Therapeutics American | N/A | |
| Suba Krishnan | Mereo BioPharma Group | 60 | |
| Andrew Gengos | Terns Pharmaceuticals | 61 | |
| Eric MD | Pliant Therapeutics | 61 | |
| Mike JD | Pliant Therapeutics | 52 | |
| Thomas Ross | Akero Therapeutics | N/A | |
| Catriona Yale | Akero Therapeutics | 53 | |
| Lauren MBA | Day One Biopharmaceuticals | 49 | |
| JD Esq | Acumen Pharmaceuticals | 54 | |
| Mark MBA | X4 Pharmaceuticals | 61 | |
| Lisa Nolan | Gossamer Bio | 63 | |
| Caroline Dupont | Biomea Fusion | N/A | |
| Michael CPA | Kiniksa Pharmaceuticals | 54 | |
Management Performance
| Return On Equity | -0.64 | |||
| Return On Asset | -0.22 |
Cymabay Therapeu Leadership Team
Elected by the shareholders, the Cymabay Therapeu's board of directors comprises two types of representatives: Cymabay Therapeu inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cymabay. The board's role is to monitor Cymabay Therapeu's management team and ensure that shareholders' interests are well served. Cymabay Therapeu's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cymabay Therapeu's outside directors are responsible for providing unbiased perspectives on the board's policies.
| BA BA, Chief Officer | ||
| Paul Quinlan, General Counsel, Corporate Secretary | ||
| Patrick OMara, Senior Development | ||
| Robert Martin, Senior Development | ||
| Sujal Shah, CFO and Secretary | ||
| Klara DickinsonEason, Chief Officer | ||
| MBA MD, Chief Officer | ||
| Ken Boehm, Senior Resources | ||
| Harish CFA, Chief Officer | ||
| Ben Kozub, Head Commercial | ||
| Charles McWherter, Chief Scientific Officer and Sr. VP | ||
| Becki Filice, Senior Leadership | ||
| Daniel Menold, Vice President - Finance, Principal Financial Officer, Principal Accounting Officer |
Cymabay Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Cymabay Therapeu a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.64 | |||
| Return On Asset | -0.22 | |||
| Operating Margin | (745.58) % | |||
| Current Valuation | 3.45 B | |||
| Shares Outstanding | 114.78 M | |||
| Shares Owned By Insiders | 0.51 % | |||
| Shares Owned By Institutions | 99.49 % | |||
| Number Of Shares Shorted | 5.85 M | |||
| Price To Earning | (8.62) X | |||
| Price To Book | 12.76 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Other Consideration for investing in Cymabay Stock
If you are still planning to invest in Cymabay Therapeu check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Cymabay Therapeu's history and understand the potential risks before investing.
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Transaction History View history of all your transactions and understand their impact on performance |